目的 探討強(qiáng)肝膠囊聯(lián)合多烯磷脂酰膽堿治膠囊治療代謝相關(guān)脂肪性肝病的臨床療效。方法 選取2021年1月—2023年3月石家莊市第二醫(yī)院收治的96例代謝相關(guān)脂肪性肝病患者，按照隨機(jī)數(shù)字表法將96例患者分為對(duì)照組和治療組，每組各48例。對(duì)照組口服多烯磷脂酰膽堿膠囊，2粒/次，3次/d。治療組在對(duì)照組基礎(chǔ)上口服強(qiáng)肝膠囊，5粒/次，2次/d，連續(xù)治療6 d后停1 d。兩組患者連續(xù)治療8周。觀察兩組的臨床療效，比較兩組的體征指標(biāo)、肝功能和血清炎癥指標(biāo)。結(jié)果 治療后，治療組的總有效率為93.75%，對(duì)照組的總有效率為79.17%，組間比較差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，兩組的體質(zhì)量指數(shù)（BMI）、腰圍顯著降低，肝/脾CT比值顯著升高（P＜0.05），且治療組的BMI、腰圍低于對(duì)照組，肝/脾CT比值高于對(duì)照組（P＜0.05）。治療后，兩組的γ-谷氨酰轉(zhuǎn)肽酶（γ-GT）、天門冬氨酸氨基轉(zhuǎn)移酶（AST）、丙氨酸氨基轉(zhuǎn)移酶（ALT）水平顯著降低（P＜0.05），且治療組的γ-GT、AST、ALT水平明顯低于對(duì)照組（P＜0.05）。治療后，兩組血清轉(zhuǎn)化生長(zhǎng)因子-β（TGF-β）、腫瘤壞死因子-α（TNF-α）、血清鐵蛋白（SF）水平顯著降低（P＜0.05），且治療組的血清TGF-β、TNF-α、SF水平低于對(duì)照組（P＜0.05）。結(jié)論 強(qiáng)肝膠囊聯(lián)合多烯磷脂酰膽堿可提高代謝相關(guān)脂肪性肝病的療效，有助于改善肝功能，降低肥胖體征，減輕炎癥反應(yīng)。

Objective To investigate the clinical effect of Qianggan Capsules combined with Polyene Phosphatidylcholine Capsules in treatment of metabolically associated fatty liver disease. Methods Patients (96 cases) with metabolically associated fatty liver disease in Shijiazhuang Second Hospital from January 2021 to March 2023 were divided into control and treatment groups according to the random number table method, and each group had 48 cases. Patients in the control group were po administered with Polyene Phosphatidylcholine Capsules, 2 grains/time, three times daily. Patients in the treatment group were po administered with Qianggan Capsules on the basis of the control group, 5 grains/time, twice daily, after continuous treatment for 6 d, stop for 1 d. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and physical indicators, liver function, and serum inflammatory indicators in two groups were compared. Results After treatment, the total effective rate of patients in the treatment group was 93.75%, while that in the control group was 79.17%, and the difference between the groups was statistically significant (P < 0.05). After treatment, BMI and waist circumference of two groups were significantly decreased, while the liver/spleen CT ratio of two groups were significantly increased (P < 0.05). BMI and waist circumference of the treatment group were lower than those of the control group, while the liver/spleen CT ratio of the treatment group was higher than that of the control group (P < 0.05). After treatment, the levels of γ-GT, AST, and ALT in two groups were significantly reduced (P < 0.05), and the levels of γ-GT, AST, and ALT in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the serum levels of TGF-β, TNF-α, and SF in two groups were significantly reduced (P < 0.05), and the serum levels of TGF-β, TNF-α, and SF in the treatment group were lower than those in the control group (P < 0.05). Conclusion Qianggan Capsules combined with Polyene Phosphatidylcholine Capsules can improve the therapeutic effect of metabolically associated fatty liver disease, help to reduce inflammation, improve liver function, reduce obesity signs.

R977

河北省醫(yī)學(xué)科學(xué)研究課題計(jì)劃項(xiàng)目(20201350)